|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM356533921 |
| 003 |
DE-627 |
| 005 |
20231226070652.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2023.109637
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1188.xml
|
| 035 |
|
|
|a (DE-627)NLM356533921
|
| 035 |
|
|
|a (NLM)37150239
|
| 035 |
|
|
|a (PII)S1521-6616(23)00136-5
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Lu, Yaxiao
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a OX40 shapes an inflamed tumor immune microenvironment and predicts response to immunochemotherapy in diffuse large B-cell lymphoma
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 23.05.2023
|
| 500 |
|
|
|a Date Revised 23.05.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023. Published by Elsevier Inc.
|
| 520 |
|
|
|a OX40 enhances the T-cell activation via costimulatory signaling. However, its molecular characteristics and value in predicting response to immunochemotherapy in DLBCL remain largely unexplored. Here, we performed an integrative analysis of sequencing and multiplex immunofluorescence staining, and discovered abnormally higher expression of OX40 in DLBCL patients. Elevated OX40 could activate T cells leading to a higher immune score for tumor immune microenvironment (TiME). OX40 upregulation simultaneously happened with immune-related genes including PD-1, CTLA4 and TIGIT et,al. Patients with high OX40 expression exhibited a lower Ann Arbor stage and IPI score and more easily achieved a complete response/partial response. The analysis of infiltrated T-cell subset revealed that patients with a greater number of CD4+/OX40+ or CD8+/OX40+ T cells had a longer OS. Our findings indicated that OX40 shapes an inflamed tumor immune microenvironment and predicts response to immunochemotherapy, providing insights for the application of OX40 agonist in DLBCL patients
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Diffuse large B-cell lymphoma
|
| 650 |
|
4 |
|a Immune microenvironment
|
| 650 |
|
4 |
|a Immunochemotherapy
|
| 650 |
|
4 |
|a OX40
|
| 650 |
|
4 |
|a T lymphocytes
|
| 700 |
1 |
|
|a Li, Yang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yu, Jingwei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Meng, Shen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bi, Chengfeng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Guan, Qingpei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Lanfang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Qiu, Lihua
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Qian, Zhengzi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhou, Shiyong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gong, Wenchen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Meng, Bin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ren, Xiubao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Armitage, James
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Huilai
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fu, Kai
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Xianhuo
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 251(2023) vom: 15. Juni, Seite 109637
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:251
|g year:2023
|g day:15
|g month:06
|g pages:109637
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2023.109637
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 251
|j 2023
|b 15
|c 06
|h 109637
|